AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39486089
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ibuzatrelvir
Trial: 39486209
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment supplemented with PNE
Trial: 39486424
Drug: Chemotherapy (carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (carboplatin plus pemetrexed)
Trial: 39486432
Drug: Valemetostat 150
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Valemetostat 150 mg per day
Trial: 39486432
Drug: Valemetostat 200
RxNorm normalized name: tazemetostat 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valemetostat 200 mg per day
Trial: 39486432
Drug: Valemetostat 250
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Valemetostat 250 mg per day
Trial: 39486432
Drug: Valemetostat 300
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Valemetostat 300 mg per day
Trial: 39486433
Drug: Valemetostat at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valemetostat at 200 mg per day in continuous 28-day cycles until disease progression or unacceptable toxicity
Trial: 39486645
Drug: MDT (definitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDT (definitive local treatment to all sites of disease, plus SOC systemic therapy)
Trial: 39486645
Drug: SOC systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC systemic therapy-only
Trial: 39486886
Drug: Selective HDAC
RxNorm normalized name: Hdac-in-4
DrugBank: CXD101 (DB16182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective HDAC inhibition in combination with immunotherapy (specifics on dosage and duration not available)
Trial: 39486892
Drug: Automated oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated oxygen administration (AOA) via the O2matic device
Trial: 39486892
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (manual oxygen administration)
Trial: 39487326
Drug: Adapalene 0.1%-clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1%-clindamycin 1% combination gel
Trial: 39487326
Drug: Clindamycin 1%
RxNorm normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 1% monotherapy
Trial: 39487337
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cilostazol daily for 7 days
Trial: 39487337
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg rosuvastatin daily for 7 days
Trial: 39487337
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 200 mg cilostazol and 20 mg rosuvastatin daily for 7 days
Trial: 39487373
Drug: Adavosertib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib (200 mg qd or 175 mg bid) plus Olaparib (200 mg bid)
Trial: 39487711
Drug: Nab-sirolimus (ABI-009)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-sirolimus (ABI-009) administered IV on days 1 and 8 of cycle 1, in combination with temozolomide (125 mg/m2) and irinotecan.
Trial: 39487711
Drug: Nab-sirolimus (ABI-009)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-sirolimus (ABI-009) at maximum tolerated dose (MTD) of 15 mg/m2.
Trial: 39488138
Drug: Vaginal laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal laser treatment (3-6 applications)
Trial: 39488138
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Vaginal laser and PFE)
Trial: 39488216
Drug: Apremilast 30
RxNorm normalized name: apremilast 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 30 mg orally twice per day after a 5-day titration period
Trial: 39488229
Drug: Integrated care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated care model (group Problem Management Plus and antidepressant therapy)
Trial: 39488549
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for genomic high-risk tumors
Trial: 39488549
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy for genomic high-risk tumors
Trial: 39488549
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy for genomic low-risk tumors
Trial: 39488549
Drug: No endocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endocrine therapy for genomic low-risk tumors
Trial: 39488682
Drug: Baseline insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline insulin
Trial: 39488682
Drug: Baseline IRS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline IRS (Insulin×0.0295 + C-peptide×0.00372)
Trial: 39488821
Drug: IcoSema (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IcoSema (175 U icodec, 0.5 mg semaglutide)
Trial: 39488821
Drug: Semaglutide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide (0.5 mg)
Trial: 39488825
Drug: Berberine; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine; specific dosage and duration not mentioned
Trial: 39489399
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment control arm with no intervention during the main study period.
Trial: 39489541
Drug: OncoPrism-HNSCC assay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OncoPrism-HNSCC assay in monotherapy cohort (n=62)
Trial: 39489541
Drug: OncoPrism-HNSCC assay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OncoPrism-HNSCC assay in chemo-immunotherapy cohort (n=50)
Trial: 39489895
Drug: Nintedanib 150
RxNorm normalized name: nintedanib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 150 mg orally twice per day (possible reduction to 100 mg twice per day in case of side-effects or hepatotoxicity) for 12 months.
Trial: 39489924
Drug: Intensified alkylating
RxNorm normalized name: petroleum alkylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified alkylating chemotherapy (IACT)
Trial: 39489924
Drug: Conventional-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose chemotherapy (CDCT)
Trial: 39490969
Drug: Serum antiglycopeptidolipid
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum antiglycopeptidolipid core IgA antibody test
Trial: 39490985
Drug: Hypotension-avoidance strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotension-avoidance strategy (target intraoperative MAP 80 mm Hg or over, hold renin-angiotensin-aldosterone system inhibitors on day of surgery and for two days after)
Trial: 39490985
Drug: Hypertension-avoidance strategy
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertension-avoidance strategy (target intraoperative MAP 60 mm Hg or more, continue all antihypertensives before and after surgery)
Trial: 39491310
Drug: ERT16 (16-session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERT16 (16-session emotion regulation therapy)
Trial: 39491310
Drug: ERT8 (8-session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERT8 (8-session emotion regulation therapy)
Trial: 39491396
Drug: Darolutamide 600
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darolutamide 600 mg twice daily (adjusted for crossover)
Trial: 39491599
Drug: Phage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phage therapy (172 pharmaceutical phage cocktails targeting Staphylococcus aureus and/or Pseudomonas aeruginosa; 57 for local injection and 99 for intravenous injection)
Trial: 39491599
Drug: Phage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phage therapy
Trial: 39491902
Drug: Transcranial focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial focused ultrasound (tfUS) targeting the right amygdala, 10-min sessions, 8 weekly sessions
Trial: 39491945
Drug: Midazolam nasal
RxNorm normalized name: midazolam Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam nasal spray (MDZ-NS) 5 mg administered for seizure clusters, with a second 5 mg dose possible if seizures did not terminate within 10 min or recurred within 10 min-6 h.
Trial: 39492363
Drug: Intravascular lithotripsy
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular lithotripsy (IVL) as adjunctive treatment in coronary angioplasty
Trial: 39492701
Drug: Tailored antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored antiplatelet therapy (early escalation with low-dose ticagrelor at 60 mg twice daily plus aspirin for <6 months, followed by late de-escalation to clopidogrel monotherapy for >6 months)
Trial: 39492701
Drug: Standard dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin for 12 months
Trial: 39492841
Drug: cadonilimab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cadonilimab at a dosage of 6 mg/kg on day 1 of each 21-day cycle combined with intravenous liposomal irinotecan at a dosage of 70 mg/m2
Trial: 39493359
Drug: Smartwatch +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartwatch + cardiac patch monitor
Trial: 39493359
Drug: Cardiac patch
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac patch monitor only
Trial: 39493729
Drug: Frequent error
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequent error augmentation physical therapy (F-EA-PT)
Trial: 39493729
Drug: Standard-of-care physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care physical therapy (SOC-PT)
Trial: 39493888
Drug: guselkumab (100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab (100 mg every 4 weeks (Q4W) or at Weeks 0, 4, and then Q8W)
Trial: 39494607
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron replacement therapy (IRT) with probiotics, specific dosage and duration not mentioned.
Trial: 39494607
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron replacement therapy (IRT) without probiotics, specific dosage and duration not mentioned.
Trial: 39495140
Drug: ECC5004 (1-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECC5004 (1-300 mg single doses in healthy volunteers; 5, 10, 30, and 50 mg multiple daily doses in patients with T2DM for 28 days)
Trial: 39495243
Drug: Inappropriate DOAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate DOAC dosing
Trial: 39666256
Drug: Appropriate DOAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate DOAC dosing
Trial: 39495467
Drug: Mitiperstat 10
RxNorm normalized name: Mitiperstat
DrugBank: Mitiperstat (DB18963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitiperstat 10 mg
Trial: 39495467
Drug: Mitiperstat (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitiperstat (all doses)
Trial: 39495531
Drug: Deferiprone 15
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone 15 mg/kg twice a day
Trial: 39495965
Drug: Survodutide (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survodutide (3.6 or 6.0 mg, once-weekly subcutaneous injections)
Trial: 39495965
Drug: Placebo (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once-weekly subcutaneous injections)
Trial: 39496199
Drug: Experimental lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental lozenges containing laccase enzyme and green coffee extract (with flavor)
Trial: 39496199
Drug: Experimental lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental lozenges containing laccase enzyme and green coffee extract (without flavor)
Trial: 39497332
Drug: Low-dose cone-beam
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cone-beam computed tomography (CBCT) protocol
Trial: 39497332
Drug: Standard-dose cone-beam
RxNorm normalized name: Pinus strobus cone extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose cone-beam computed tomography (CBCT) protocol
Trial: 39497751
Drug: Crizanlizumab 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizanlizumab 5.0 mg/kg
Trial: 39497751
Drug: Crizanlizumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizanlizumab 7.5 mg/kg
Trial: 39498340
Drug: Digoxin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.25 mg every other day) combined with csDMARDs for 6 months
Trial: 39499011
Drug: 68 Ga-HBED-CC-exendin-4
RxNorm normalized name: Ga-Psma-hbed-CC Ga-68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68 Ga-HBED-CC-exendin-4
Trial: 39499142
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 400 mg twice daily for 6 months
Trial: 39499437
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of individual session at baseline and group session 3 months later
Trial: 39500299
Drug: Blended cognitive
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended cognitive behavioural intervention (combination of a web-based program and sessions with a psychologist)
Trial: 39500883
Drug: JMT103 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMT103 (2 mg/kg) administered subcutaneously every four weeks, with loading doses on days 8 and 15.
Trial: 39500896
Drug: Vincristine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine treatment
Trial: 39501351
Drug: Lurasidone (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (median dosage 37.00 mg/day at baseline, increased to 74.00 mg/day at 3 months)
Trial: 39501388
Drug: Tocilizumab (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (280 mg intravenous single dose)
Trial: 39501831
Drug: Angong Niuhuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angong Niuhuang Pills (ANP) 3 g/day for 5 days
Trial: 39501831
Drug: Angong Niuhuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angong Niuhuang Pills (ANP)
Trial: 39501831
Drug: Angong Niuhuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angong Niuhuang Pills (ANP) in patients with large artery atherosclerosis
Trial: 39502029
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment effect of PCI versus CABG
Trial: 39502066
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K Antagonist
Trial: 39502135
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 IU X3/day)
Trial: 39503770
Drug: Targeting NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeting NO bioavailability in CD36 deficiency
Trial: 39503798
Drug: Pharmacist-guided deprescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-guided deprescribing of antihypertensive medications
Trial: 39503798
Drug: Family physician-guided
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Family physician-guided treatment adjustments
Trial: 39504016
Drug: Olmesartan/Amlodipine single-pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan/Amlodipine single-pill combination (SPC) therapy
Trial: 39504023
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of mRNA COVID-19 vaccine and quadrivalent inactivated influenza vaccine (IIV4)
Trial: 39504023
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of mRNA COVID-19 vaccine and quadrivalent inactivated influenza vaccine (IIV4)
Trial: 39504023
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration
Trial: 39504023
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration
Trial: 39504025
Drug: Increased nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased nicotine replacement therapy intensity (4-week combination nicotine patch plus nicotine lozenge)
Trial: 39504025
Drug: Increased nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased nicotine replacement therapy intensity (2-week nicotine patch)
Trial: 39504520
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group (standard-care treatment delayed until intrauterine pregnancy was confirmed)
Trial: 39504548
Drug: Remote Patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote Patient Monitoring (RPM+) with digital therapeutics (DTx) solution
Trial: 39504548
Drug: Remote Patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote Patient Monitoring (RPM-) without digital therapeutics (DTx) solution
Trial: 39505121
Drug: Gamification intervention
RxNorm normalized name: Gamifant
DrugBank: Emapalumab (DB14724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gamification intervention informed by behavioral economic concepts; participants receive a wearable fitness tracker and set a goal to increase daily step count by 1,500-3,000 steps from baseline; intervention duration is 6 months.
Trial: 39505279
Drug: Peanut oral
RxNorm normalized name: Peanut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut oral immunotherapy (n=95) for 24 months
Trial: 39505279
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg peanut (PN-300) for 12 months (n=30)
Trial: 39506293
Drug: SPP-continuation (n=24);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPP-continuation (n=24); SPP in month 1, continuation treatment in month 2
Trial: 39506529
Drug: Ponatinib (PON)
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ponatinib (PON) 30 mg/day in chronic phase (CP-CML)
Trial: 39506529
Drug: Ponatinib (PON)
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ponatinib (PON) 45 mg/day in accelerated/blastic phase (AP/BP-CML)
Trial: 39506647
Drug: Ballet technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ballet technique intervention (one-hour classes twice per week for six weeks)
Trial: 39506737
Drug: Combination approach
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination approach
Trial: 39507037
Drug: PD-1/PD-L1 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 inhibitors with baseline bone metastasis (BoM)
Trial: 39507037
Drug: PD-1/PD-L1 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 inhibitors without baseline bone metastasis (BoM)
Trial: 39507039
Drug: TQB2450 (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 (1,200 mg) plus anlotinib (8 mg)
Trial: 39507039
Drug: TQB2450 (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 (1,200 mg) plus placebo
Trial: 39507456
Drug: Vasopressor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressor therapy
Trial: 39507857
Drug: Active Low
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Low Intensity Shockwave Therapy (LiSWT)
Trial: 39507860
Drug: Low-intensity shockwave
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity shockwave therapy (LiSWT), treated twice weekly for 3 consecutive weeks with a Storz device.
Trial: 39507860
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (control group), patients crossed over at 1 month and were unblinded.
Trial: 39508144
Drug: Low-dose intracoronary
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intracoronary adenosine
Trial: 39508144
Drug: High-dose intracoronary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intracoronary adenosine (HDIC)
Trial: 39508283
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment for UTI
Trial: 39509108
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment (randomization to early treatment)